Overview of Naproxen Aurobindo

Property	Description
Active ingredient	Naproxen Sodium
Form	Oral Tablet
Pharmacological class	Nonsteroidal Anti-Inflammatory Drug (NSAID)
General purpose	Relief from pain, inflammation, and fever
Origin	Synthetic, Propionic acid derivative

Defining Naproxen Aurobindo: Classification and Active Ingredient

Naproxen Aurobindo is defined as a synthetic medicinal compound classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), a class of medication clinically recognized for its analgesic and anti-inflammatory effects. The sole active ingredient in this preparation is Naproxen Sodium (INN), which falls under the specific chemical subclass of propionic acid derivatives. Unlike non-NSAID analgesics, this compound's mechanism is fundamentally rooted in its capacity to interrupt the enzymatic production of prostaglandins, the endogenous lipids that mediate pain and inflammation signals. As a specific product, the Aurobindo formulation is supplied as an oral tablet and is generally accessible as a prescription-only (Rx) product, distinguishing its controlled distribution compared to low-dose over-the-counter alternatives in some markets.

Composition, Form, and General Purpose

The drug’s composition utilizes the sodium salt form, Naproxen Sodium, which structural pharmacological studies have confirmed facilitates more effective dissolution and rapid systemic absorption compared to the Naproxen free acid. Naproxen Aurobindo is manufactured using solid pharmaceutical excipients to deliver the active substance in a consistent oral tablet form. The therapeutic identity of the drug is characterized by its triple capacity as an analgesic (to relieve discomfort), an antipyretic (to reduce fever), and an anti-inflammatory agent (to mitigate swelling and tenderness). For example, it provides relief in typical scenarios characterized by musculoskeletal discomfort or general inflammatory processes. The primary action of Naproxen is through reversible inhibition of the Cyclooxygenase (COX) enzyme system. Therefore, the core purpose of the drug is to modulate the body’s inflammatory response and provide general symptomatic relief.

What side effects are possible with Naproxen Aurobindo?

Possible Side Effects and Safety Information

This section summarizes the adverse reactions and essential safety information for Naproxen Aurobindo, strictly based on official government regulatory documents.

Serious and Clinically Significant Risks

Regulatory documentation highlights two principal warnings:

Serious Cardiovascular Thrombotic Events: Use of this medicine is associated with an increased risk of heart attack ( myocardial infarction) and stroke, which can be fatal. This risk may increase with duration of use and in patients with pre-existing cardiovascular disease. It is contraindicated for use in the setting of coronary artery bypass graft ( CABG) surgery.
Serious Gastrointestinal Adverse Events: The medicine increases the risk of serious events such as bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur without warning symptoms.

Common Adverse Reactions

Adverse reactions classified as Common in regulatory data typically involve gastrointestinal and nervous system disturbances. These may include, but are not limited to, headache, dyspepsia (indigestion), nausea, vomiting, dizziness, constipation, and vertigo.

Safety Restrictions and Monitoring

The medicine is contraindicated in patients with a known history of hypersensitivity (e.g., asthma, hives, or allergic-type reactions) to aspirin or other non-steroidal anti-inflammatory drugs ( NSAIDs). Due to potential harm to the fetus, it is also contraindicated starting at 30 weeks of pregnancy (the third trimester).

Regulatory safety notes indicate that specific monitoring may be required for patients with pre-existing conditions affecting the heart, kidneys, and liver, including regular assessment of blood pressure, renal function, and hepatic function, due to the documented potential for systemic toxicity.

Overdose and Emergency Response

Officially documented manifestations of an overdose with Naproxen Sodium, the active ingredient in Naproxen Aurobindo, are primarily centered on the gastrointestinal and central nervous systems. Initial signs may include epigastric pain, nausea, and vomiting. Central nervous system presentations documented in regulatory labeling include headache, drowsiness, confusion, dizziness, and tinnitus.

Severe or life-threatening outcomes are officially listed and necessitate urgent medical intervention. These serious manifestations can involve gastrointestinal bleeding or perforation, acute renal failure, and severe neurological events such as seizures and coma. Elderly patients and individuals with pre-existing renal or hepatic impairment are specifically noted in regulatory documents as being at an increased risk for severe toxicity.

As there is no specific antidote known for acute Naproxen toxicity, government regulatory sources mandate that immediate medical attention must be sought upon any suspected overdose. Emergency services or a Poison Control Center should be contacted without delay. Management described in official prescribing information is symptomatic and supportive. Procedures may include gastric emptying measures, administration of activated charcoal to reduce absorption, and continuous clinical monitoring, including assessment of vital signs and potentially ECG tracking.

Therapeutic Uses of Naproxen Aurobindo

Naproxen is relevant in conditions presenting with systemic or localized discomfort and inflammatory processes. Naproxen Aurobindo is commonly used across therapeutic domains where additional symptomatic support is needed, primarily to ease the burden of symptoms related to physical discomfort and inflammatory states.

This medication is applied in assisting with the symptomatic burden of long-term inflammatory conditions, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis. It is also relevant for easing acute and recurrent manifestations such as acute gout attacks, painful tendinitis or bursitis, and episodic discomfort like primary dysmenorrhea (menstrual cramps).

The medication helps address symptom clusters that may become disruptive, such as stiffness, swelling, and chronic joint pain. This contributes to improved comfort during periods of heightened symptoms and helps maintain a sense of stability when symptoms are more noticeable.

“Supportive relief may be provided when symptoms interfere with routine activities.”

Quick Fact: Support for Inflammatory Discomfort

Naproxen Aurobindo may assist with managing symptoms related to inflammatory or irritative states and systemic fever. It supports the patient during difficult episodes by easing distress and contributing to easing the overall symptom load.

Regulatory References

NIH DailyMed overview

Eligibility and Restrictions for Use

Naproxen Aurobindo, a non-steroidal anti-inflammatory drug (NSAID), is generally suitable for most adults but is strictly contraindicated for specific patient populations and clinical states.

Populations for Whom Use is Prohibited (Contraindicated)

Use is prohibited for individuals with a known allergy or hypersensitivity to naproxen, aspirin, or other NSAIDs, particularly if they have a history of asthma, rhinitis, or hives resulting from previous NSAID use. The medicine must not be used in patients with an active peptic ulcer, active gastrointestinal bleeding, or a history of recurrent ulceration/hemorrhage. It is also prohibited for patients with severe heart failure, severe liver failure, or severe renal failure (creatinine clearance <30 ml/minute).

Naproxen Aurobindo is contraindicated for treating peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery and during the last trimester of pregnancy (at or after 30 weeks gestation).

Restricted or Special Consideration Populations

Use is not recommended or requires special medical consideration for:

Elderly or debilitated patients, who face an increased risk of serious gastrointestinal events.
Patients with uncontrolled hypertension, congestive heart failure (mild to moderate), or certain established cardiovascular diseases.
Patients with impaired renal or hepatic function (avoidance is required for severe impairment).
Women who are breastfeeding or who are about 20 to 30 weeks pregnant (use should be limited and carefully considered).

Safety and effectiveness for most Naproxen Aurobindo formulations have not been established for the general pediatric population (e.g., typically under two years of age, or five to sixteen years for some forms, depending on the indication).

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Naproxen Aurobindo

Interaction Scope

Property	Official Regulatory Statement
Medicinal product categories with documented interactions	NSAIDs, Anticoagulants, Anti-platelet Agents, SSRIs/SNRIs, Corticosteroids, ACE Inhibitors, ARBs, Diuretics, Quinolone Antibiotics, Cardiac Glycosides.
Specific interacting medicines (if explicitly listed)	Aspirin (analgesic dose), Probenecid, Warfarin, Lithium, Methotrexate, Digoxin, Furosemide, Ciclosporin, Tacrolimus, Ketorolac.
Mechanistic basis of interactions	Pharmacokinetic Interaction: Reduced clearance leading to increased plasma levels. Pharmacodynamic Interaction: Additive effect resulting in amplified risk, primarily concerning bleeding or renal function.
Timing-based interaction rules	Mifepristone: Must not be used for 8 to 12 days after mifepristone administration.
Population-specific interaction notes	Concomitant use with ACE Inhibitors or ARBs in elderly, volume depleted, or renally impaired patients may result in a deterioration of renal function.
Interaction-related restrictions	Alcohol consumption increases the risk of gastrointestinal blood loss. Co-administration with analgesic doses of aspirin or other NSAIDs is not generally recommended.

Interaction Classifications (High-Level)

Classification	Official Regulatory Statement
Interaction severity classification	Contraindicated (Peri-operative CABG pain); Not Recommended/Should be Avoided (Other NSAIDs, Analgesic Aspirin); Use with Caution/Monitoring Required (Lithium, Methotrexate, Anticoagulants).
Regulatory basis	Information is derived from U.S. Food and Drug Administration (FDA) Prescribing Information and European Summary of Product Characteristics (SmPC).
Interaction-context constraints	Peri-operative CABG surgery: Contraindicated immediately before and after the procedure. Gastrointestinal Risk: Increased risk of ulceration and bleeding when combined with SSRIs, Anti-platelet Agents, or Corticosteroids.

Resulting Interaction Structure

The regulatory documents define the product’s interaction structure through established patterns of pharmacokinetic alterations and pharmacodynamic risk summation. Naproxen reduces the clearance of certain drugs, such as Lithium and Methotrexate, which results in documented increases in their plasma concentrations. The use with Anticoagulants (e.g., Warfarin), SSRIs, and Corticosteroids is associated with an amplified risk of hemorrhage or gastrointestinal bleeding. These documented patterns establish mandatory timing requirements (e.g., Mifepristone) and set classifications for co-administration, from restricted to requiring caution.

Mechanism of Action

The mechanism of Naproxen Sodium is centered on the reversible, competitive inhibition of the Cyclooxygenase ( COX-1 and COX-2) enzymes. This molecular interference prevents the enzymes from converting the substrate, Arachidonic Acid, into Prostaglandin and Thromboxane mediators. By blocking COX-2 activity, the drug significantly reduces the biosynthesis of Prostaglandin E2 ( PGE2) at sites of injury. The reduction in PGE2 decreases the sensitization of peripheral nociceptors and limits local vascular changes, thereby modulating the activity within pain and inflammatory signal transduction pathways. The drug also acts centrally by reducing PGE2 levels in the hypothalamus. This molecular action resets the elevated thermoregulatory set-point, triggering physiological heat dissipation mechanisms. Due to the molecule's non-selective binding profile, the inhibition inherently extends to the protective functions mediated by COX-1, a functional consequence that simultaneously affects the homeostatic production of Prostaglandins regulating critical physiological processes.

Dosage and Administration Information

Official Administration Guidelines for Naproxen Aurobindo

Administration of Naproxen Aurobindo tablets, which contain Naproxen Sodium, must strictly adhere to established guidelines. The foundational rule for use is to employ the lowest effective dose for the shortest duration necessary.

Parameter	Official Instruction
Route of Administration	Oral administration only (swallowed whole).
Dosing Principle	Use the lowest effective dose for the shortest duration.
Timing in Relation to Meals	Tablets should be taken preferably with or after food and swallowed with a drink of water.
Max Dose (Chronic Use)	The total daily dose is typically 500 mg to 1,000 mg, not to exceed 1,500 mg for limited periods (up to 6 months).

Dosing for Specific Contexts

Naproxen dosing is adjusted based on the condition being addressed, often involving a higher initial dose for acute events:

Chronic Conditions: Dosing is typically twice daily (e.g., 250 mg to 500 mg twice a day). The morning and evening doses may be adjusted relative to one another based on predominant symptoms.
Acute Pain/Dysmenorrhea: An initial loading dose (e.g., 500 mg naproxen base or 550 mg naproxen sodium) is often recommended, followed by smaller doses every 6 to 12 hours as needed, without exceeding the specific total daily maximum.
Acute Gout: Treatment starts with a high initial dose (e.g., 750 mg naproxen base or 825 mg sodium), followed by smaller, periodic doses (e.g., 250 mg or 275 mg every 8 hours) until the attack has subsided.

Population-Specific Use

Dose adjustments are indicated for certain populations. A lower dose should be considered for older adults and patients with renal or hepatic impairment. For Polyarticular Juvenile Idiopathic Arthritis (PJIA), the recommended total daily dose is approximately 10 mg/kg of body weight, given in two divided doses.

Note: Do not use Naproxen Aurobindo concomitantly with other naproxen-containing products.

Recent Clinical Evidence

Evaluating Naproxen Aurobindo's Potential Role

Research has examined whether Naproxen Aurobindo is a potential treatment for patients with a specific chronic condition. The research typically focuses on how participants respond to a prescribed regimen over periods such as six months.

Studies have included large-scale evaluations focused on mobility outcomes. For example, one study assessed whether the drug affected mobility in participants displaying advanced symptoms. This research also reported on the duration of changes observed in overall symptom severity. Separately, investigators explored whether combining Naproxen Aurobindo with Therapy mathbfB was associated with a change in pain reports among participants.

Safety and Tolerability Profiles

Naproxen Aurobindo is one of the treatments researchers have examined for this condition. Study findings report on the frequency of adverse events associated with the drug, often describing them as mild to moderate.

Side Effect	Reported Frequency
Headache	30%
Mild Nausea	25%
Fatigue	15%

These events were generally described as temporary in the research reports. A trial specifically compared the drug with existing treatments and reported on the findings regarding the frequency of side effects. Additionally, the drug was evaluated for its potential effect on severe complications associated with the condition.

Administration Protocol in Research

Studies described a protocol where participants took Naproxen Aurobindo twice daily at a dose of 10 mg. Study participants were typically monitored for liver function at baseline and monthly intervals throughout the research period. Research did not include or specifically evaluated outcomes for people with Kidney Disease. Findings described the time to onset of changes after starting the 10 mg regimen.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Naproxen Aurobindo (FAQ)

Q: Why is Naproxen Aurobindo generally described as a longer-acting medication than other NSAIDs?

Naproxen has a prolonged presence in the body, with an elimination half-life reported to be between 12 and 17 hours. This pharmacokinetic characteristic supports its classification as a long-acting NSAID, often associated with less frequent dosing intervals, compared to many other non-steroidal anti-inflammatory drugs.

Q: How is Naproxen Aurobindo different from other medications in the non-steroidal anti-inflammatory drug (NSAID) class?

Official product information indicates that naproxen is a non-selective inhibitor of the Cyclooxygenase (COX) enzymes, similar to ibuprofen. Its key difference lies in its longer elimination half-life compared to several other NSAIDs. Official risk profiles classify it as having an intermediate risk for gastrointestinal ulceration.

Q: What is the approximate duration of anti-inflammatory effect provided by Naproxen Aurobindo?

The therapeutic effect of the drug, which includes relief from pain and inflammation, is reported in regulatory documents to last for approximately 12 hours. This duration is consistent with its long half-life, which enables less frequent administration.

Q: Is there a known association between Naproxen Aurobindo use and an increase in blood pressure?

Regulatory safety warnings state that naproxen may cause an increase in blood pressure or worsen pre-existing high blood pressure (hypertension). Due to this possibility, regular monitoring of blood pressure may be necessary for some patients.

Q: Can Naproxen Aurobindo cause a person to retain water or experience swelling (edema)?

Official adverse drug reaction listings indicate that fluid retention, known as edema (swelling), is a potential side effect of naproxen. Official guidance indicates that special medical consideration may be required for individuals with pre-existing conditions involving fluid retention.

Q: What type of skin reactions, such as rashes or hives, have been associated with naproxen?

Regulatory side effect information includes the possibility of common skin reactions such as a rash or itching. More serious adverse reactions, which include severe blistering, hives, or signs of a serious allergic reaction, are also possible and require immediate attention.

Q: Can Naproxen Aurobindo cause a ringing sound in the ears (tinnitus)?

Official safety information includes ringing or buzzing in the ears, known as tinnitus, as a reported side effect of naproxen.

Q: What are the signs of potential liver issues that have been officially associated with naproxen use?

Official warnings list several signs associated with potential liver problems. These may include nausea, pain in the upper stomach area, fatigue, dark-colored urine, and yellowing of the skin or eyes (jaundice).

Q: Is Naproxen Aurobindo appropriate for managing pain in children under the age of 12?

According to regulatory monographs, the safety and effectiveness of naproxen for the general pediatric population have not been established for children under 12 years of age. The lack of established safety means that use is generally restricted in this age group, unless specifically prescribed for an approved pediatric indication.

Q: How does the risk of kidney-related problems change with long-term use of Naproxen Aurobindo?

Official risk factors state that the risk of serious adverse effects, including potential kidney problems, may be amplified by the longer duration of use and higher doses of the medicine. Regulatory documents emphasize that the risk of serious adverse effects is managed by administering the lowest effective dose for the shortest duration.

Q: What is the difference in strength or concentration between prescription Naproxen Aurobindo and over-the-counter naproxen?

Regulatory documents distinguish between the available strengths for different distribution channels. Over-the-counter (OTC) products are generally available as 220 mg tablets, while prescription strengths are generally higher.

Q: Does Naproxen Aurobindo interfere with the protective effects of low-dose aspirin taken for heart health?

Official drug interaction warnings indicate that naproxen may decrease the antiplatelet (cardioprotective) effects of low-dose aspirin. Because of this potential interaction, official warnings advise that combining these medicines requires special consideration due to the potential for decreased antiplatelet effect.

Q: What research themes exist regarding Naproxen Aurobindo's effect on female fertility?

Official product information states that naproxen, which works by inhibiting prostaglandin synthesis, may temporarily impair fertility in women who are trying to conceive. This official guidance also notes that this effect is expected to be reversible after discontinuing the medicine.

Q: What should a person do if they suspect an allergic reaction to Naproxen Aurobindo?

If signs of an allergic reaction (such as hives, difficulty breathing, or swelling of the face or throat) occur, it is important that the use of the drug is stopped immediately, and emergency medical help is sought.

Q: Why do regulatory bodies advise against taking Naproxen Aurobindo for more than a few days without consulting a healthcare professional?

For non-prescription (self-medication) use, regulatory guidance requires consultation with a healthcare professional if pain persists for more than five days or if fever lasts for more than three days. This time limit is designed to ensure that the underlying cause of persistent symptoms is medically evaluated.

Q: What is the scientific basis for taking Naproxen Aurobindo twice a day? (Focus on duration of action)

The drug's elimination half-life, which is the time it takes for half of the dose to leave the body, is documented to be between 12 and 17 hours. This prolonged half-life is the scientific basis that supports its dosing schedule of twice daily to maintain effective therapeutic concentrations in the body.

How should Naproxen Aurobindo be stored and disposed of?

How to Store and Dispose of Naproxen Aurobindo?

This medication must be stored according to specific regulatory requirements to maintain its stability and effectiveness. Official labeling mandates storage below 25°C (or 77 F) and requires the product to be protected from light and moisture. To achieve this, the tablets should be kept in their original packaging—either the blister pack or the container—and the container must be tightly closed when not in use.

Disposal

For disposal of any unused or expired Naproxen Aurobindo, you should follow local requirements for discarding medicinal products. It is recommended to use an established drug take-back program if one is available in your area. If a take-back program is not accessible, the product should be disposed of in the household trash, after being mixed with an undesirable substance (such as dirt or used coffee grounds) and placed into a sealed bag or container. This is consistent with regulatory guidance for medicines not on the flush list.

Naproxen Aurobindo